They were the first company to take all of the practical knowledge and lived wisdom from philanthropically funded researchers, pivot to for profit, and meanwhile convince the leader of the most loved/popular mdma non-profit to do the same. Now we have COMPASS + Lykos… Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company… announced that…
…from a financial perspective, the inconsistency of psychedelic experiences and the fact that they require hands-on psychological therapy make for a difficult investment pitch. Treatment is typically administered in a specialized facility under supervision by psychiatric professionals, which is costlier and harder to scale up than simply providing medicine. The industry’s market performance reflects such…
MAPS PBC [Public Benefit Corporation] and COMPASS Pathways collaborated to work with the AMA [American Medical Association] to create these new CPT III codes. These are temporary codes assigned to emerging technologies, services and procedures, to facilitate reimbursement and support access to psychedelic therapies in the United States, if such therapies receive regulatory approval by the…
[Compass Pathways; synthetic-psilocybin patenting British bio-tech company]… a securities purchase agreement with a select group of healthcare specialist investors for the private placement of… American Depositary Shares… Morgan Stanley and TD Cowen are acting as the placement agents for the private placement. The securities to be sold in the private placement, including the ADSs underlying…
Christian Angermayer (billionaire) owns an extensive art collection that includes ancient artifacts highlighting the role that psychedelics have played in human history… that is, the inventors’ definition controls, “even if it is contrary to the conventional meaning of the term” according to Christopher G. Paulraj, Tina E. Hulse, & Sheridan K. Snedden… the U.S. Patent…
The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following the approval of a joint application submitted by MAPS PBC [partnered with MAPS and Rick Doblin] and [Peter Theil & Christian Angermayer backed] COMPASS Pathways… On March 3 [2023], the AMA published its Panel Actions summary which included…
London-based Compass Pathways PLC, which has adopted the conventional biotech strategy of modifying naturally existing psilocybin into a patentable drug and taking it through clinical trials. The firm, founded in 2020, boasted a stock market value of $2 billion in November 2021, but its shares since have slumped 80 percent. Small Pharma, a small Canadian…
The analog of psilocybin that Gilgamesh is developing has been designed to eliminate the hallucinogenic experiences that are often set off by so-called magic mushrooms. Researchers working with the company [including team members from ATAI, Pfizer, Johnson & Johnson, etc], administer test drugs [new chemical entities] to mice and then capture their reactions using video…
Compass… phase 2B data, which has yet to be formally published in a peer-reviewed journal… with five patients (6.3%) in the 25-mg group and six patients (8%) in the 10-mg group experiencing serious adverse events during the follow-up period…. These adverse events included suicidal ideation and suicidal behavior. The first Phase 3 trial has been…
Robin Feldman, an expert on pharmaceutical intellectual property at the University of California Hastings College of Law… …said the conflict over psychedelics reflects the larger problems of a patent system that saddles Americans with some of the highest prescription drug prices in the world. “It’s not pretty when you look under the hood,” she said.…
Recent Comments